This article was originally published in The Tan Sheet
Matrixx Initiatives cites the introduction of new products along with the "ongoing growth" of the Zicam line in its announcement to increase fiscal year 2005 guidance Dec. 13. The company expects total revenues for 2005 to grow 45%-50% over fiscal 2004 (up from the original 25%-35%), and earnings per share to increase 35%-45% (up from 10%-20%). "This year's positive results include our increased marketing activity to build consumer awareness and trial for the Zicam brand," Matrixx CEO Carl Johnson says. "They also reflect the strong introductory support of the new Nasal Comfort products." The firm reported that retail sales of Zicam products increased 37% for the twelve-week period ended Nov. 27, while the total cough/cold category grew 2% compared to the prior-year period...
You may also be interested in...
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.